Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

S7800 CpG WIZ® p16 - Methylation specific PCR assay

The CpG WIZ p16 Amplification Kit is used for determining the methylation status of the p16 promoter by methylation-specific PCR (MSP).

CpG WIZ® p16 - Methylation specific PCR assay MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
S7800
25 assays  
Purchase on Sigma-Aldrich

Overview

Replacement Information
Description
Catalogue NumberS7800
Brand Family Chemicon®
Trade Name
  • CpG Wiz
  • Chemicon
DescriptionCpG WIZ® p16 - Methylation specific PCR assay
OverviewExpression of p16*, a tumor suppressor gene, is repressed in a variety of cancers such as bladder, colon and retinoblastoma. Methylation of CpG islands in the p16 promoter has been shown to be responsible for inactivation of this gene in certain cases. The CpG WIZ® p16 Amplification Kit is used for determining the methylation status of the p16 promoter by methylation-specific PCR (MSP). The kit contains primers targeted to regions of the promoter where the sequences are most divergent after bisulfite treatment. PCR parameters have been identified such that all primer sets in the kit amplify under the same conditions. Control genomic DNA samples (methylated and unmethylated) for p16 are also included.

Methylation-specific PCR (MSP) is a new technology for sensitive detection of abnormal gene methylation utilizing small amounts of DNA (Herman, 1996 ). This process employs an initial bisulfite reaction to modify the DNA, followed by PCR amplification with specific primers designed to distinguish methylated from unmethylated DNA.

*p16 is covered under U.S. patents 5,801,236, 5,843,756, and 6,090,578.
References
Product Information
Quality LevelMQ100
Applications
ApplicationThe CpG WIZ p16 Amplification Kit is used for determining the methylation status of the p16 promoter by methylation-specific PCR (MSP).
Key Applications
  • PCR
Application NotesPrinciples of the Technique

Use of either the CpGenome™ DNA Modification Kit (Cat. No. S7820) or the CpGENOME™ Fast DNA Modification Kit (Cat. No. S7824) facilitates the initial bisulfite reactions, while the CpG WIZ® p16 Amplification Kit contains the reagents required for the gene-specific PCR amplification reactions.
Biological Information
Species Reactivity
  • Human
Entrez Gene Number
Entrez Gene SummaryThis gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM1, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.
Gene Symbol
  • CDKN2A
  • p14ARF
  • TP16
  • p16
  • CDKN2
  • MTS1
  • P16
  • INK4a
  • CMM2
  • MLM
  • ARF
  • p16INK4a
  • INK4
  • p16-INK4a
  • p14
  • p16-INK4
  • p16INK4A
  • p16INK4
  • p19
  • p19ARF
  • CDK4I
  • MTS-1
UniProt Number
UniProt SummaryFUNCTION: SwissProt: Q8N726 # Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2- induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development.| P42771 # Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.


SIZE: 173 amino acids; 18006 Da

SUBUNIT: Does not interact with cyclins, CDC2, CDK2, CDK4, CDK5 or CDK6. Binds to BCL6, E2F1, HUWE1, MDM2, MYC, NPM1/B23, TOP1/TOPOI and UBE2I/UBC9. Interacts with TBRG1.

SUBCELLULAR LOCATION: Nucleus, nucleolus (By similarity).





DISEASE: SwissProt: P42771 # Defects in CDKN2A are involved in tumor formation in a wide range of tissues. & Defects in CDKN2A are the cause of cutaneous malignant melanoma 2 (CMM2) [MIM:155601]. Inheritance is autosomal dominant. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a preexisting benign nevus, which occurs most often in the skin but also may involve other sites. & Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719]. & Defects in CDKN2A are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. & Defects in CDKN2A are the cause of melanoma-astrocytoma syndrome [MIM:155755]. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.

SIMILARITY: SwissProt: P42771 ## Belongs to the CDKN2 cyclin-dependent kinase inhibitor family. & Contains 4 ANK repeats.
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Packaging Information
Material Size25 assays
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
S7800 08436037123399

Documentation

CpG WIZ® p16 - Methylation specific PCR assay MSDS

Title

Safety Data Sheet (SDS) 

References

Reference overviewPub Med ID
Expression and methylation pattern of p16 in neuroblastoma tumorigenesis.
Safiye Aktas,Aydan Cavusoglu Celebiler,Zeynep Zadeo?lulari,Gulden Diniz,Aydanur Kargi,Nur Olgun
Pathology oncology research : POR  16  2009

Show Abstract 		19466588 19466588

Brochure

Title
Shaping Epigenetics Discovery - Epigenetics Product Selection Brochure